Edesa Biotech, Inc.
Every calculator, already run for EDSA
Open the full toolkit →You have the numbers on EDSA. Get the argument.
A written report on which of these readings actually decide the outcome for Edesa Biotech, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
2 analysts covering EDSAAnalyst Price Target Disagreement for Edesa Biotech, Inc.
Wall Street's bull case implies +293% from the current price; the bear case implies +68%. A 224% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Edesa Biotech, Inc.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate…
EDSA — frequently asked
Is EDSA a buy right now?
Wall Street's consensus rating on Edesa Biotech, Inc. is Strong Buy across 2 analysts, with a mean price target of $16.33 (+205% vs. the current $5.35). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Edesa Biotech, Inc.?
Analysts covering Edesa Biotech, Inc. (EDSA) range from a bear-case target of $9.00 to a bull-case high of $21.00, with a mean consensus target of $16.33 across 3 analysts. The spread of $12.00 (224% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Edesa Biotech, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Edesa Biotech, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full EDSA research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Edesa Biotech, Inc., in minutes. 3 free reports included with every account — no credit card required.